Modality
ASO
MOA
Anti-Tau
Target
PCSK9
Pathway
Hedgehog
Wilms
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Nov 2029
Phase 1Current
NCT06335883
929 pts·Wilms
2018-11→2029-11·Recruiting
NCT08293709
2,039 pts·Wilms
2017-05→2027-02·Recruiting
2,968 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-0510mo awayPh2 Data· Wilms
2029-11-263.7y awayPh2 Data· Wilms
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2027-02-05 · 10mo away
Wilms
Ph2 Data
2029-11-26 · 3.7y away
Wilms
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06335883 | Phase 1/2 | Wilms | Recruiting | 929 | PANSS |
| NCT08293709 | Phase 1/2 | Wilms | Recruiting | 2039 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |